{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:52:23Z","timestamp":1779205943450,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,9]],"date-time":"2015-05-09T00:00:00Z","timestamp":1431129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00262-015-1706-4","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T08:00:56Z","timestamp":1431072056000},"page":"977-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Joseph P.","family":"Balint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth S.","family":"Gabitzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Latchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald L.","family":"Messerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,9]]},"reference":[{"key":"1706_CR1","author":"M Vergati","year":"2010","unstructured":"Vergati M, Intrivici C, Huen N-Y, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol. doi: 10.1155\/2010\/596432","journal-title":"J Biomed Biotechnol"},{"key":"1706_CR2","author":"C Palena","year":"2010","unstructured":"Palena C, Schlom J (2010) Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol. doi: 10.1155\/2010\/380697","journal-title":"J Biomed Biotechnol"},{"key":"1706_CR3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djs033","volume":"104","author":"J Schlom","year":"2012","unstructured":"Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599\u2013613","journal-title":"J Natl Cancer Inst"},{"key":"1706_CR4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616\u2013629","journal-title":"Mol Ther"},{"key":"1706_CR5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","volume":"24","author":"DS Bangari","year":"2006","unstructured":"Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849\u2013862","journal-title":"Vaccine"},{"key":"1706_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652307780859062","volume":"7","author":"SK Campos","year":"2007","unstructured":"Campos SK, Barry MA (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7:189\u2013204","journal-title":"Curr Gene Ther"},{"key":"1706_CR7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","volume":"6","author":"N Chirmule","year":"1999","unstructured":"Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574\u20131583","journal-title":"Gene Ther"},{"key":"1706_CR8","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch DH, Kikc SV, Weverling GJ et al (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203\u20135209","journal-title":"Vaccine"},{"key":"1706_CR9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.gt.3300378","volume":"4","author":"A Amalfitano","year":"1997","unstructured":"Amalfitano A, Chamberlain JS (1997) Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 4:258\u2013263","journal-title":"Gene Ther"},{"key":"1706_CR10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.72.2.926-933.1998","volume":"72","author":"A Amalfitano","year":"1998","unstructured":"Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72:926\u2013933","journal-title":"J Virol"},{"key":"1706_CR11","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1128\/JVI.73.9.7835-7841.1999","volume":"73","author":"D Hartigan-O\u2019Connor","year":"1999","unstructured":"Hartigan-O\u2019Connor D, Amalfitano A, Chamberlain JS (1999) Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 73:7835\u20137841","journal-title":"J Virol"},{"key":"1706_CR12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/14712590903307388","volume":"9","author":"SS Seregin","year":"2009","unstructured":"Seregin SS, Amalfitano A (2009) Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus based vectors. Expert Opin Biol Ther 9:1521\u20131531","journal-title":"Expert Opin Biol Ther"},{"key":"1706_CR13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/cgt.2009.17","volume":"16","author":"T Osada","year":"2009","unstructured":"Osada T, Yang XY, Hartman ZC et al (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16:673\u2013682","journal-title":"Cancer Gene Ther"},{"key":"1706_CR14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00262-010-0847-8","volume":"59","author":"ES Gabitzsch","year":"2010","unstructured":"Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR (2010) Anti-tumor immunity despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 59:1131\u20131135","journal-title":"Cancer Immunol Immunother"},{"key":"1706_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2008.11.003","volume":"122","author":"ES Gabitzsch","year":"2009","unstructured":"Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A, Jones FR (2009) A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 122:44\u201351","journal-title":"Immunol Lett"},{"key":"1706_CR16","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1016\/j.vaccine.2009.06.028","volume":"27","author":"ES Gabitzsch","year":"2009","unstructured":"Gabitzsch ES, Yu X, Yoshida LH, Balint J, Amalfitano A, Jones FR (2009) Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27:6394\u20136398","journal-title":"Vaccine"},{"key":"1706_CR17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/cgt.2010.82","volume":"18","author":"ES Gabitzsch","year":"2011","unstructured":"Gabitzsch ES, Xu Y, Balcaitis S, Balint JP Jr, Jones FR (2011) An Ad5 [E1-, E2b-]-HER2\/neu vector induces immune responses and inhibits HER2\/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 18:326\u2013335","journal-title":"Cancer Gene Ther"},{"key":"1706_CR18","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1016\/j.vaccine.2011.08.038","volume":"29","author":"ES Gabitzsch","year":"2011","unstructured":"Gabitzsch ES, Xu Y, Balint JP Jr, Balcaitis S, Sanders-Beer B, Jones FR (2011) Induction and comparison of SIV immunity in Ad5 Na\u00efve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine 29:8101\u20138107","journal-title":"Vaccine"},{"key":"1706_CR19","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1016\/j.vaccine.2011.07.073","volume":"29","author":"FR Jones","year":"2011","unstructured":"Jones FR, Gabitzsch ES, Xu Y et al (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020\u20137026","journal-title":"Vaccine"},{"key":"1706_CR20","first-page":"001","volume":"S4","author":"ES Gabitzsch","year":"2011","unstructured":"Gabitzsch ES, Jones FR (2011) New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations. J Clin Cell Immunol S4:001. doi: 10.4172\/2155-9899.S4-001","journal-title":"J Clin Cell Immunol"},{"key":"1706_CR21","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1016\/j.vaccine.2012.09.058","volume":"30","author":"ES Gabitzsch","year":"2012","unstructured":"Gabitzsch ES, Balint JP Jr, Xu Y et al (2012) Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. Vaccine 30:7265\u20137270","journal-title":"Vaccine"},{"key":"1706_CR22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/cgt.2012.55","volume":"19","author":"BG Wieking","year":"2012","unstructured":"Wieking BG, Vermeer DW, Spanos WC et al (2012) A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther 19:667\u2013674","journal-title":"Cancer Gene Ther"},{"key":"1706_CR23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","volume":"62","author":"MM Morse","year":"2013","unstructured":"Morse MM, Chaudhry A, Gabitzsch ES et al (2013) Novel adenoviral vector induces T cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 62:1293\u20131301","journal-title":"Cancer Immunol Immunother"},{"key":"1706_CR24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/jcla.1860050510","volume":"5","author":"JA Thompson","year":"1991","unstructured":"Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344\u2013366","journal-title":"J Clin Lab Anal"},{"key":"1706_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstrom","year":"1999","unstructured":"Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67\u201381","journal-title":"Semin Cancer Biol"},{"key":"1706_CR26","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2002.08.017","volume":"20","author":"NL Berinstein","year":"2002","unstructured":"Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197\u20132207","journal-title":"J Clin Oncol"},{"key":"1706_CR27","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323\u20135337","journal-title":"Clin Cancer Res"},{"key":"1706_CR28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.13.40","volume":"12","author":"SR Gameiro","year":"2013","unstructured":"Gameiro SR, Jammeh ML, Hodge JW (2013) Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev Vaccines 12:617\u2013629","journal-title":"Expert Rev Vaccines"},{"key":"1706_CR29","first-page":"4570","volume":"57","author":"S Zaremba","year":"1997","unstructured":"Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570\u20134577","journal-title":"Cancer Res"},{"key":"1706_CR30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.194.6.833","volume":"194","author":"S Tangri","year":"2001","unstructured":"Tangri S, Ishioka GY, Huang X et al (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild type peptide. J Exp Med 194:833\u2013846","journal-title":"J Exp Med"},{"key":"1706_CR31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1706_CR32","unstructured":"CTEP Cancer Therapy Evaluation Program (2010) CTCAE and CTC website http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm . Accessed 10 Feb 2012"},{"key":"1706_CR33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-1759(00)00191-5","volume":"240","author":"FH Rininsland","year":"2000","unstructured":"Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M (2000) Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240:143\u2013155","journal-title":"J Immunol Methods"},{"key":"1706_CR34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-1-14","volume":"1","author":"K Shafer-Weaver","year":"2003","unstructured":"Shafer-Weaver K, Sayers T, Strobl S et al (2003) The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 1:14\u201323","journal-title":"J Transl Med"},{"key":"1706_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v21.i1-3.190","volume":"21","author":"AC Hobeika","year":"2001","unstructured":"Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA (2001) Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 21:287\u2013297","journal-title":"Crit Rev Immunol"},{"key":"1706_CR36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002371-200501000-00008","volume":"28","author":"AC Hobeika","year":"2005","unstructured":"Hobeika AC, Morse MA, Osada T et al (2005) Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 28:63\u201372","journal-title":"J Immunother"},{"key":"1706_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3727\/095535491820873191","volume":"3","author":"AH Cory","year":"1991","unstructured":"Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium\/formazan assay for cell growth assays in culture. Cancer Comm 3:207\u2013212","journal-title":"Cancer Comm"},{"key":"1706_CR38","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"1706_CR39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757\u20131765","journal-title":"N Engl J Med"},{"key":"1706_CR40","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Cutsem Van","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"1706_CR41","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory\u00a0prostate cancer. J Clin Oncol 24:3089\u20133094","journal-title":"J Clin Oncol"},{"key":"1706_CR42","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","volume":"115","author":"CS Higano","year":"2009","unstructured":"Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670\u20133679","journal-title":"Cancer"},{"key":"1706_CR43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"1706_CR44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804\u2013811","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-015-1706-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1706-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:32:30Z","timestamp":1599003150000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-015-1706-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,9]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s00262-015-1706-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,9]]}}}